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ABSTRACT 
 
   Aim: To evaluate the feasibility of treatment method (intraperitoneal administration of radiolabelled 
monoclonal antibody) for patients with gastric cancer. 
   Method: A total of 15 eligible patients, with histologically proven adenocarcinoma of the stomach 
or gastro-oesophageal junction, who had undergone resection to remove the primary tumour mass, 
were enrolled in the study. Eight patients were treated with the study drug and 7 of patients were 
enrolled into the standard care control arm. 
   Materials and Results: Mean blood radioactivity peaked between 36 and 48 hours, with a mean 
peak value of approximately 15% ID. Data previously reported on intraperitoneal Y-HMFG1 treatment 
of patients with ovarian cancer show peak values of 25 - 35% ID seen at 48 hour post-injection. 
The present results require confirmation in a large population of gastric cancer patients, but suggest 
that the transfer of radioactivity into the blood pool is decreased compared with the ovarian cancer 
patients. 
   Conclusions: A HAMA response was detected in all patients after treatment, and there is some 
suggestion that is follows a bi-phasic pattern. If  as hypothesised, a HAMA response provides a boost 
to the immune system, leading to a potential longer term benefit, then the HAMA response seen in this 
study following pemtumomab treatment is encouraging. 
 
   Key words: gastric cancer, intraperitoneal infusion, radiolabelled monoclonal antibody. 
 
INTRODUCTION 
 
   Gastric cancer is a leading cause of can-
cer death, with five-year survival rates 
in the USA currently below 15%. The pri-
mary mode of treatment is surgery, 
and recently post-operative chemoradia-
tion has been proposed as a regimen 
to prolong survival [1].   
 
   Pemtumomab is a HMFG1 murine 
monoclonal antibody radiolabelled with 
Yttrium-90 (Y-HMFG1). The antibody 
targets the MUC1 protein, which is ex-
pressed by a high proportion of gastric 
carcinomas. High levels of MUC1 expre-
ssion have been correlated with pro-
gression and poor prognosis [2]. 
 
   After surgery for gastric cancer, relapse 
and disease progression frequently occur 
within the peritoneal cavity. It is proposed 
that intraperitoneal administration of pem-
tumomab could prevent progression 
of the disease or improve survival in pa-
tients with minimal disease after resection. 
Previous experience with this treatment 
suggests that  it is more readily tolerated 
than chemotherapy, and in an earlier 
phase-II study, adjuvant use of intra-
peritoneal pemtumomab in ovarian cancer 
patients (who also often show intra-
peritoneal disease on relapse) improved 
survival in comparison with conventional 
treatment [3]. 
 
STUDY DESCRIPTION  
 
   The aim the 15 TARGET-1 (Targeted 
Antibody Radioimmunotherapy Gastric 
Evaluation Trial) study is to determine 
the safety, tolerability and preliminary 
efficacy of a single dose of intraperito- 
neally administered pemtumomab (25 mg 
antibody labeled with up to 1110 MBq 
Yttrium-90) in the treatment of gastric 
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cancer. This is a randomized, pilot phase-
II trial comparing best supportive care 
(standard care) with study medication, 
conducted at centers in Poland and UK. 
 
METHODS 
 
   A total of 15 eligible patients, with histo-
logically proven adenocarcinoma of the sto-
mach or gastro-oesophageal junction, 
who had undergone resection to remove 
the primary tumour mass, were enrolled 
in the study. Eight patients were treated 
with the study drug and 7 were enrolled 
into the standard care control arm. Ethics 
approval was sought and obtained at all 
centers prior to enrolling patients. 
All patients provided a written informed 
consent prior to entrolment. Patient 
demographics are shown in Table 1. 
 
 
Table 1. Patient's characteristic in the study. 
 
Patient # Sex Age at entry Stage 
of disease 
Randomisation 
T4 M 80 T4N2 Standard Care 
T5 M 63 T3N2 Standard Care 
T7 M 55 T3N1 Standard Care 
T9 M 61 T3N0 Study drug 
T10 F 61 T2N0M1 Study drug 
T11 M 71 T3N0 Standard Care 
T12 M 50 T3N3 Standard Care 
T13 M 55 T3N2 Study drug 
T14 M 63 T2N1 Study drug 
T16 F 48 T3N0 Standard Care 
T17 M 74 T3N2 Study drug 
T19 F 62 T3N1 Standard Care 
T20 M 74 T3N0 Study drug 
T21 M 69 T3N2 Study drug 
 
 
   The patients under treatment underwent 
a second-look laparoscopy to assess their 
disease status and place the treat- 
ment catheter. An individualised dose 
(666 MBq/m2 body surface area, up to 
1110 MBq maximum) of pemtumomab 
was administered intraperitoneally 
in a saline infusion (approx. 1L). Blood 
and urine samples were collected from 
the patients over the first few days post-
treatment and analysed for levels of ra-
dioactivity. Patients were then followed up 
on a weekly basis for 8 weeks, at week 
12 and at 3 monthly intervals thereafter 
for up to 1 year. 
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RESULTS 
 
   Preliminary data were collected when 
the last enrolled patient completed 
the three month follow-up, and are repor-
ted here. The study will complete 
a 12-month follow-up for all patients during 
2003, and full data will be reported then. 
Pharmacokinetic data 
 
   Samples were collected for 5/8 
of the patients treated over the first 4 days 
post-treatment. Blood radioactivity values 
from individual patients with means 
(and SDs) are indicated in Figure 1. 
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Fig. 1. Blood Radioactivity vs Time Profile: Mean (+/-SD) & Individual Values for 5 patients. 
 
 
   Approximately 5% of the injected was 
excreted in the urine over the first 
24 hours, with a further 2% ID on day 2. 
   Mean blood radioactivity peaked be-
tween 36 and 48 hours, with a mean peak 
value of approximately 15% ID. Data 
previously reported on intraperitoneal 
Y-HMFG1 treatment of patients with 
ovarian cancer [4] show peak values 
of 25-35% ID seen at 48 hour post-
injection. The present results require 
confirmation in a large population of gas-
tric cancer patients, but suggest that 
the transfer of radioactivity into the blood 
pool is decreased compared with the 
ovarian cancer patients. This finding could 
reflect either (a) greater impairment 
of lymphatic drainage associated with 
the initial surgery or (b) residual disease 
at second-look and treatment (The ovarian 
patients were free of macroscopic disease 
at treatment). 
 
BLOOD PARAMETERS 
  
   It is known that the treatment with 
90Y radiolabelled antibodies can have 
an effect on haematological parameters. 
Individual data points and mean values 
for platelet and white blood cell levels 
(n=8) following treatment are shown 
in Figures 2 and 3. 
   The White Blood Cell nadir occurred 
at 7-8 weeks post-treatment at NCI grade 
1-2; recovery was spontaneous and no in-
tervention was required. An additional, 
earlier dip was seen at weeks 3-4 after-
treatment. 
   The pattern of haematological toxicity 
appears similar to that seen previously 
in ovarian cancer patients [4]. 
 
HUMAN ANTI MOUSE ANTIBODY 
(HAMA) RESPONSE 
 
   Treatment of patients with murine 
monoclonal antibodies often generates 
an immunological response in patients, 
known as the HAMA response. 
   Rashes, arthralgia and myalgia have 
been associated with such treatment 
(Maraveyas 1994). In this study, the pre-
scription of analgesics and antihistamines 
at one week post-treatment was intended 
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to control these effects. To date, there 
have been three incidences of rash 
(one serious), and one event of myalgia 
reported in the patients treated. 
   The assay of the patients’ blood 
for HAMA titres (Boehringer-Mannheim 
assay, which detects human antibodies 
against all mouse IgG subclasses-IgG1, 
IgG2a, IgG2b, IgG3) shows that all 
the treated patients seem to develop 
a HAMA response after week 1, 
suggesting that gastric cancer is not 
immunosuppressive. Individual patient 
results are shown in Figure 4. 
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Fig. 2. Platelet Count Following Pemtumomab Treatment. 
 
 
   The platelet nadir occurred at week 5, 
was typically grade 0-2 (NCl), and re-
covery was spontaneous with no inter-
vention required. 
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Fig. 3. White Blood Cell Count Following Pemtumomab Treatment. 
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Fig. 4. Individual HAMA Titres Following Pemtumomab Treatment. 
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   The limited data currently available 
suggest a bi-phasic HAMA response, 
although further evaluation is required. 
It may be that the initial HAMA  response 
at later timepoints. 
   It has been hypothesised that, in addi-
tion to any immediate effects mediated by 
the targeted delivery of radioisotopes, 
murine monoclonal antibodies may induce 
a potential longer term benefit via a boost 
to the immune system provided by the 
HAMA response [5,6]. If this hypothesis is 
correct, then the HAMA response in seen 
these gastric cancer patients following 
pemtumomab treatment is encouraging. 
ADVERSE EVENT PROFILE  
 
There have been a total of 63 adverse 
events (of all causalities) recorded to date, 
of which 43 were in the Study Drug group 
(10 Serious) and 20 in the Standard Care 
group (6 Serious). Of these, the most 
common adverse event recorded was 
abdominal pain, followed by nausea and 
diarrhoea. Such events were expected 
during this study as they have also been 
reported following treatment of the ovarian 
cancer patients in earlier studies. 
 
 
Table. 2. Reported Adverse Events with incidence > 1. 
 
Study Drug Standard Care 
Adverse Event Description 
Serious Non-serious Serious Non-serious 
Abdominal 1 3  1 
Nausea  2 1 2 
Diarrhoea  4   
Abdominal discomfort  1  2 
Intestinal obstruction 2  1  
Rash 1 2   
Vomiting  1 1 1 
Abdominal pain upper 1 1   
Dizziness  2   
Influenza like illness  2   
Pneumonia  1 1  
Thrombocytopenia 1 1   
 
 
   The therapeutic study medication co-
nsisted of 25 mg of HMFG1 antibody 
labeled with 90Yttrium to deliver a dose 
of 666 MBq/m2 (18 mCi/m2) of a body 
surface, but not greater than 1110 MBq 
(30 mCi) in total. A kit containing the study 
medication was delivered to the hospital. 
The kit contained two bottles: one with 
HMFG1 antibody, and the other with 
HMFG1-CITC-DTPA immunoconjugate. 
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The kit was ready for radiolabeling 
procedure. All components were mixed 
in proper proportions, time and tempera-
ture. After stating the purity of the medi-
cation, using chromatography, the syringe 
was filled with physiological salt up 
to 10 cm3. The medication was ready 
to apply through the catheter to the ab-
domen. The time of application was one 
minute.   
   All solutions were sterile and the la-
beling, purification and dispensing pro-
cesses were performed in an environment 
accurate for preparing radioactive ma-
terials, such as the nuclear medicine 
department and the department of medical 
physics.  
   All processes were performed in the nu-
clear medicine department in the hospital.  
The radiopharmacist was properly pro-
tected from radiation, wearing a lead 
apron, a single use lab coat, lead glasses, 
single use rubber gloves, a lead collar 
for the thyroid gland and a dosimeter 
attached to the lead apron. The syringe 
with the medication was protected with 
a special plexi shield. Because of the ra-
dioactive nature and a short half-life, 
90Yttrium was delivered to the hospital right 
before the treatment. Until the end 
of the treatment the patient was placed 
in a separated room. Measurements 
of doses were performed using a Portable 
Dose Ratemeter type PDR2 made by NE 
Technology Limited. The dosimeter was 
calibrated to measure the irradiation of 90Y. 
The measurements were carried out within 
24, 48, 72 and 96 hours after the appli-
cation of the medication, 10 cm from 
the patient’s skin above the catheter. After 
the first 24 hours after the application, 
the dose rate was 22,4 µSv/h, after 
48 hours it was 5,3 µSv/h. After 72 hours, 
the dose rate was 3,76 µSv/h. On the last 
day of measurements the dose rate was 
2,34 µSv/h. 
   The accumulated radioactive and me-
dical wastes were also measured. After 
the measurements the wastes were 
transported to the storage and kept there 
until  the loss of their radioactivity.  
   The dose rate of wastes was 1 µSv/h. 
The greater part of 90Y was excreted from 
the organism. Radioimmuinoisotope was 
bound with cancer cells. After four days 
from the application the radioactivity 
decreased to the level that allowed the pa-
tient to leave the hospital.  
 
CONCLUSION 
  
   The interim analysis of the data from 
the TARGET-1 study suggests that in gas-
tric cancer patients treatment with 
intraperitoneal is generally well tolerated. 
   The platelet nadir occurred at week 5, 
was typically grade 0-2 (NCI), and re-
covery was spontaneous with no inter-
vention required, a pattern similar to the 
previously reported for ovarian cancer 
patients. 
   A HAMA response was detected in all 
patients after treatment, and there is some 
suggestion that is follows a bi-phasic 
pattern. If, as hypothesised, a HAMA res-
ponse provides a boost to the immune 
system, leading to a potential longer term 
benefit, then the HAMA response seen 
in this study following pemtumomab 
treatment is encouraging. 
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